Approval · Notice of Compliance 33249 · 2024
APO-GABAPENTIN: Notice of Compliance 33249
Issued May 10, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33249
- Date
- May 10, 2024
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Updates to the Product Monograph
- Canadian reference product
- NEURONTIN
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APO-GABAPENTIN | Not yet assigned | — |
| APO-GABAPENTIN TABLETS | Not yet assigned | — |
Medicinal ingredients
- GABAPENTIN 100 MG per CAP
- GABAPENTIN 300 MG per CAP
- GABAPENTIN 400 MG per CAP
- GABAPENTIN 600 MG per TAB
- GABAPENTIN 800 MG per TAB